159 related articles for article (PubMed ID: 36326180)
1. Machine learning to improve prognosis prediction of metastatic clear-cell renal cell carcinoma treated with cytoreductive nephrectomy and systemic therapy.
Yang W; Ma L; Dong J; Wei M; Ji R; Chen H; Xue X; Li Y; Jin Z; Xu W; Ji Z
Biomol Biomed; 2023 May; 23(3):471-482. PubMed ID: 36326180
[TBL] [Abstract][Full Text] [Related]
2. Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
de Bruijn R; Wimalasingham A; Szabados B; Stewart GD; Welsh SJ; Kuusk T; Blank C; Haanen J; Klatte T; Staehler M; Powles T; Bex A
Eur Urol Oncol; 2020 Apr; 3(2):168-173. PubMed ID: 31956080
[TBL] [Abstract][Full Text] [Related]
3. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
4. Selection of Optimal Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Predictive Model Based on SEER Database.
Zhang Y; Hu J; Yang J; Xie Y; Chen Z; Shangguan W; Han J; He W; Yang J; Zheng Z; Zhong Q; Zhu D; Xie W
Front Oncol; 2022; 12():814512. PubMed ID: 35127544
[TBL] [Abstract][Full Text] [Related]
5. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a prognostic nomogram for predicting cancer-specific survival in patients with metastatic clear cell renal carcinoma: A study based on SEER database.
Huang G; Liao J; Cai S; Chen Z; Qin X; Ba L; Rao J; Zhong W; Lin Y; Liang Y; Wei L; Li J; Deng K; Li X; Guo Z; Wang L; Zhuo Y
Front Oncol; 2022; 12():949058. PubMed ID: 36237316
[TBL] [Abstract][Full Text] [Related]
8. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
[TBL] [Abstract][Full Text] [Related]
9. Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma.
Rosiello G; Knipper S; Palumbo C; Dzyuba-Negrean C; Pecoraro A; Mazzone E; Mistretta FA; Tian Z; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Int Urol Nephrol; 2019 Dec; 51(12):2181-2188. PubMed ID: 31468289
[TBL] [Abstract][Full Text] [Related]
10. Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach.
Laukhtina E; Schuettfort VM; D'Andrea D; Pradere B; Quhal F; Mori K; Sari Motlagh R; Mostafaei H; Katayama S; Grossmann NC; Rajwa P; Karakiewicz PI; Schmidinger M; Fajkovic H; Enikeev D; Shariat SF
World J Urol; 2022 Mar; 40(3):747-754. PubMed ID: 34671856
[TBL] [Abstract][Full Text] [Related]
11. The Construction and Validation of a new Predictive Model for Overall Survival of Clear Cell Renal Cell Carcinoma Patients with Bone Metastasis Based on Machine Learning Algorithm.
Le Y; Xu W; Guo W
Technol Cancer Res Treat; 2023; 22():15330338231165131. PubMed ID: 37078130
[TBL] [Abstract][Full Text] [Related]
12. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma.
Roussel E; Verbiest A; Milenkovic U; Van Cleynenbreugel B; Van Poppel H; Joniau S; Beuselinck B; Albersen M
Scand J Urol; 2020 Dec; 54(6):493-499. PubMed ID: 32924729
[TBL] [Abstract][Full Text] [Related]
13. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.
Xiao WJ; Zhu Y; Dai B; Zhang HL; Ye DW
Int Braz J Urol; 2015; 41(2):288-95. PubMed ID: 26005970
[TBL] [Abstract][Full Text] [Related]
14. A Population Study to Identify Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Sarcomatoid Renal Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database.
Ji B; Li D; Fu S; Zhang Z; Yang T; Wu Y; Zuo Y; Xu Z; Yu N
Med Sci Monit; 2020 Jun; 26():e921297. PubMed ID: 32516796
[TBL] [Abstract][Full Text] [Related]
15. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
[TBL] [Abstract][Full Text] [Related]
16. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Marconi L; de Bruijn R; van Werkhoven E; Beisland C; Fife K; Heidenreich A; Kapoor A; Karam J; Kauffmann C; Klatte T; Ljungberg B; Matin S; Sjoberg D; Staehler M; Stewart GD; Tanguay S; Uzzo R; Welsh S; Wood L; Wood C; Bex A
World J Urol; 2018 Dec; 36(12):1973-1980. PubMed ID: 30069581
[TBL] [Abstract][Full Text] [Related]
17. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
[TBL] [Abstract][Full Text] [Related]
18. Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
Laukhtina E; Pradere B; D'Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Schuettfort VM; Enikeev D; Shariat SF
Minerva Urol Nephrol; 2022 Jun; 74(3):329-336. PubMed ID: 33769012
[TBL] [Abstract][Full Text] [Related]
19. Metastatic renal cell carcinoma patients of T4 stage who are in status of N1 stage or older than 76 years cannot benefit from cytoreductive nephrectomy.
Zhang Z; Wu H; Yang T; Wu Y; Yu N; Xu Z
BMC Cancer; 2020 Sep; 20(1):844. PubMed ID: 32883242
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]